OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 788-798
Open Access | Times Cited: 41
Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, et al.
Leukemia (2023) Vol. 37, Iss. 4, pp. 788-798
Open Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
A new genomic framework to categorize pediatric acute myeloid leukemia
Masayuki Umeda, Jing Ma, Tamara Westover, et al.
Nature Genetics (2024) Vol. 56, Iss. 2, pp. 281-293
Open Access | Times Cited: 34
Masayuki Umeda, Jing Ma, Tamara Westover, et al.
Nature Genetics (2024) Vol. 56, Iss. 2, pp. 281-293
Open Access | Times Cited: 34
Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system
Haixiao Zhang, Xinhui Zheng, Wenwen Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Haixiao Zhang, Xinhui Zheng, Wenwen Guo, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia
Yujun Chen, Yu Zhao, Mingyue Yao, et al.
Acta Pharmacologica Sinica (2025)
Open Access | Times Cited: 1
Yujun Chen, Yu Zhao, Mingyue Yao, et al.
Acta Pharmacologica Sinica (2025)
Open Access | Times Cited: 1
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3512-3512
Open Access | Times Cited: 16
Eleonora Boscaro, Irene Urbino, Federica Maria Catania, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3512-3512
Open Access | Times Cited: 16
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Leukemia (2023) Vol. 38, Iss. 1, pp. 45-57
Open Access | Times Cited: 15
Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, et al.
Leukemia (2023) Vol. 38, Iss. 1, pp. 45-57
Open Access | Times Cited: 15
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
Ga‐Young Song, Hyeon-Jong Kim, Tae‐Hyung Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Ga‐Young Song, Hyeon-Jong Kim, Tae‐Hyung Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
Carlos Jiménez‐Vicente, Paola Charry, Sandra Castaño‐Díez, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 256-267
Closed Access | Times Cited: 5
Carlos Jiménez‐Vicente, Paola Charry, Sandra Castaño‐Díez, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 256-267
Closed Access | Times Cited: 5
Limited Quality of Life Sacrifice for Optimizing long-term Survival: The Impact of p-ALG Compared to r-ATG in High-Risk Hematological Malignancy Patients Undergoing Matched Sibling Donor Transplantation
Lingyan Yan, Linli Lu, Liwen Wang, et al.
Cytotherapy (2025)
Closed Access
Lingyan Yan, Linli Lu, Liwen Wang, et al.
Cytotherapy (2025)
Closed Access
Optimal Therapeutic Strategies in Relapsed/Refractory AML with Prior Exposure to Venetoclax-Based Therapy
Sawyer Bawek, Matthew Burwinkel, Prutha Patel, et al.
Leukemia Research (2025) Vol. 150, pp. 107643-107643
Closed Access
Sawyer Bawek, Matthew Burwinkel, Prutha Patel, et al.
Leukemia Research (2025) Vol. 150, pp. 107643-107643
Closed Access
Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute Myeloid Leukaemia Trial (CAVEAT)
Chong Chyn Chua, Sun Loo, Chun Yew Fong, et al.
Blood Advances (2025)
Open Access
Chong Chyn Chua, Sun Loo, Chun Yew Fong, et al.
Blood Advances (2025)
Open Access
Integrated Genomics Reveal Potential Resistance Mechanisms of PANoptosis‐Associated Genes in Acute Myeloid Leukemia
Cong Liang, Zhi‐Qing Long, Mengjie Lei, et al.
Molecular Carcinogenesis (2025)
Closed Access
Cong Liang, Zhi‐Qing Long, Mengjie Lei, et al.
Molecular Carcinogenesis (2025)
Closed Access
The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry
Ιωάννα Λαζανά, Maria Papathanassiou, Ioannis Konstantellos, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 667-667
Open Access
Ιωάννα Λαζανά, Maria Papathanassiou, Ioannis Konstantellos, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 667-667
Open Access
Maintenance Therapy in AML : What Is the Future Potential?
Hannah Goulart, Andrew H. Wei, Tapan M. Kadia
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 38-49
Open Access
Hannah Goulart, Andrew H. Wei, Tapan M. Kadia
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 38-49
Open Access
Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram
Yiran Fang, Miaomiao Zhao, Ting Luo, et al.
Annals of Hematology (2025)
Open Access
Yiran Fang, Miaomiao Zhao, Ting Luo, et al.
Annals of Hematology (2025)
Open Access
Potential value of immunogenic cell death related-genes in refining European leukemiaNet guidelines classification and predicting the immune infiltration landscape in acute myeloid leukemia
Changqing Jiao, Xiaoyu Ma, Jianling Cui, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Changqing Jiao, Xiaoyu Ma, Jianling Cui, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
Hasmukh Jain, Thomas Eipe, Alok Shetty, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Hasmukh Jain, Thomas Eipe, Alok Shetty, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemia
Catana Allert, Carsten Müller‐Tidow, Maximilian Felix Blank
International Journal of Cancer (2023) Vol. 154, Iss. 2, pp. 197-209
Open Access | Times Cited: 11
Catana Allert, Carsten Müller‐Tidow, Maximilian Felix Blank
International Journal of Cancer (2023) Vol. 154, Iss. 2, pp. 197-209
Open Access | Times Cited: 11
Circular RNAs: pivotal role in the leukemogenesis and novel indicators for the diagnosis and prognosis of acute myeloid leukemia
Atefe Rahmati, Alireza Mafi, Firooze Soleymani, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Atefe Rahmati, Alireza Mafi, Firooze Soleymani, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Stellae-123 gene expression signature improved risk stratification in Taiwanese acute myeloid leukemia patients
Yu‐Hung Wang, Adrián Mosquera Orgueira, Chien‐Chin Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Yu‐Hung Wang, Adrián Mosquera Orgueira, Chien‐Chin Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Christoph Röllig
Hematology (2023) Vol. 2023, Iss. 1, pp. 175-185
Closed Access | Times Cited: 5
Christoph Röllig
Hematology (2023) Vol. 2023, Iss. 1, pp. 175-185
Closed Access | Times Cited: 5
Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China
Enbo Chen, Changqing Jiao, Jian Yu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 21615-21626
Open Access | Times Cited: 5
Enbo Chen, Changqing Jiao, Jian Yu, et al.
Cancer Medicine (2023) Vol. 12, Iss. 24, pp. 21615-21626
Open Access | Times Cited: 5
Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
Mihee Kim, Seo-Yeon Ahn, Tae‐Hyung Kim, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Mihee Kim, Seo-Yeon Ahn, Tae‐Hyung Kim, et al.
Hematology (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia
Jaja Zhu, Hippolyte Guérineau, Anne‐Margaux Lefebvre‐Fortané, et al.
FEBS Journal (2024)
Open Access | Times Cited: 1
Jaja Zhu, Hippolyte Guérineau, Anne‐Margaux Lefebvre‐Fortané, et al.
FEBS Journal (2024)
Open Access | Times Cited: 1
Acute Myeloid Leukemia Genomics: Impact on Care and Remaining Challenges
Ann‐Kathrin Eisfeld, Elaine R. Mardis
Clinical Chemistry (2024) Vol. 70, Iss. 1, pp. 4-12
Closed Access | Times Cited: 1
Ann‐Kathrin Eisfeld, Elaine R. Mardis
Clinical Chemistry (2024) Vol. 70, Iss. 1, pp. 4-12
Closed Access | Times Cited: 1
